GlassScriptPhysician profile
Andrew P Cease
NPI 1346660149
$4,640.70
in general payments reported to CMS, 2019-2025
39 companies · $964 in 2025
The $964 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $289 · 2021: $488 · 2022: $629 · 2023: $981 · 2024: $1,031 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,975.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,281.24 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $505.75 | 2020-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $427.35 | 2022-2025 | |
| Livanova USA, INC. | $297.54 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $268.82 | 2019-2023 | |
| Immedica Pharma US, INC. | $242.48 | 2022-2024 | |
| Catalyst Pharmaceuticals, INC. | $208.69 | 2023-2025 | Fycompa |
| Supernus Pharmaceuticals, INC. | $176.49 | 2019-2023 | Qelbree |
| Acadia Pharmaceuticals INC | $170.66 | 2024-2025 | Daybue |
| Sunovion Pharmaceuticals INC. | $82.15 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $68.61 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $66.41 | 2023 | Aptiom |
| Biogen, INC. | $65.95 | 2024-2025 | Skyclarys |
| Upsher-Smith Laboratories LLC | $64.81 | 2021-2025 | |
| Sk Life Science, INC. | $62.97 | 2024-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.